FDMT Q3 2022 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$500,000-63.4% YoY

Gross Profit

-$18M-3688.0% margin

Operating Income

-$26M-5299.0% margin

Net Income

-$26M-5138.2% margin

EPS (Diluted)

$-0.74

QoQ Revenue Growth

+208.6%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$23M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$280M

Total Liabilities

$29M

Stockholders' Equity

$251M

Cash & Equivalents

$108M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$500,000	$1M	-63.4%
Gross Profit	-$18M	-$14M	-27.4%
Operating Income	-$26M	-$23M	-16.9%
Net Income	-$26M	-$22M	-15.5%

Geographic Segments

NETHERLANDS

$497,00099%

UNITED STATES

$3,0001%